PHASE II STUDY OF EVEROLIMUS (E) IN REFRACTORY GERM CELL TUMORS (GCTS)

被引：0
|
作者：
Reckova, M. [1 ]
Mego, M. [1 ]
Svetlovska, D. [1 ]
Miskovska', V. [2 ]
Obertova, J. [1 ]
Sycova-Mila, Z. [1 ]
Palacka, P. [1 ]
Rajec, J. [1 ]
Liskova, S. [1 ]
Mardiak, J. [1 ]
机构：
[1] Natl Canc Inst, Bratislava, Slovakia
[2] St Elisabeth Canc Inst, Bratislava, Slovakia
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：293 / 293
页数：1
相关论文
共 50 条
  • [21] Phase II study of oxaliplatin (O) and bevacizumab (B) chemotherapy in refractory germ cell tumors (GCT)
    Ramasubbaiah, R.
    Brames, J.
    Johnston, E. L.
    Einhorn, L. H.
    Aughn, D. J.
    Perkins, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] A phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors.
    Bedano, PM
    Brames, MJ
    Williams, SW
    Einhorn, LH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 384S - 384S
  • [23] Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial
    Mego, M.
    Svetlovska, D.
    De Angelis, V
    Kalavska, K.
    Lesko, P.
    Makovnik, M.
    Obertova, J.
    Orszaghova, Z.
    Palacka, P.
    Reckova, M.
    Rejlekova, K.
    Sycova-Mila, Z.
    Mardiak, J.
    Chovanec, M.
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1080 - 1086
  • [24] Phase II study of Disulfiram and Cisplatin in Refractory Germ Cell Tumors. The GCT-SK-006 phase II trial
    M Mego
    D Svetlovska
    De Angelis V
    K Kalavska
    P Lesko
    M Makovník
    J Obertova
    Z Orszaghova
    P Palacka
    M Rečková
    K Rejlekova
    Sycova-Mila Z
    J Mardiak
    M Chovanec
    Investigational New Drugs, 2022, 40 : 1080 - 1086
  • [25] Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors
    Kondagunta, GV
    Bacik, J
    Schwartz, L
    Sheinfeld, J
    Bajorin, D
    Vuky, J
    Marion, S
    Mazumdar, M
    Bosl, GJ
    Motzer, RJ
    INVESTIGATIONAL NEW DRUGS, 2004, 22 (02) : 177 - 179
  • [26] Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors
    Vuky, J
    McCaffrey, J
    Ginsberg, M
    Mariani, T
    Bajorin, DF
    Bosl, GJ
    Motzer, RJ
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (03) : 265 - 267
  • [27] Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors
    Feldman, Darren R.
    Kondagunta, G. Varuni
    Ginsberg, Michelle S.
    Ishill, Nicole
    Patil, Sujata
    Cestaro, John
    Obbens, Eugenie
    Sheinfeld, Joel
    Bosl, George J.
    Motzer, Robert J.
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (05) : 487 - 490
  • [28] Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors
    G. Varuni Kondagunta
    Jennifer Bacik
    Lawrence Schwartz
    Joel Sheinfeld
    Dean Bajorin
    Jacqueline Vuky
    Stephanie Marion
    Madhu Mazumdar
    George J. Bosl
    Robert J. Motzer
    Investigational New Drugs, 2004, 22 : 177 - 179
  • [29] PHASE-II TRIAL OF MITOGUAZONE IN PATIENTS WITH REFRACTORY GERM-CELL TUMORS
    CHUN, H
    BOSL, GJ
    CANCER TREATMENT REPORTS, 1985, 69 (04): : 461 - 462
  • [30] Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors
    Darren R. Feldman
    G. Varuni Kondagunta
    Michelle S. Ginsberg
    Nicole Ishill
    Sujata Patil
    John Cestaro
    Eugenie Obbens
    Joel Sheinfeld
    George J. Bosl
    Robert J. Motzer
    Investigational New Drugs, 2007, 25 : 487 - 490
12345